Synthetic biology holds immense promise for sustainable chemical production through engineered microorganisms, yet commercialization has seen limited success globally due to economic and technical challenges. Fermelanta has developed proprietary platform technology that introduces over 20 genes into highly productive E. coli, enabling the biosynthesis of complex compounds via multi-step pathways from inexpensive raw materials. This technology delivers economically viable production while ensuring high quality and sustainability. As an alternative to costly, low-purity, and environmentally harmful chemical synthesis and plant extraction methods, Fermelanta is driving a paradigm shift in industrial infrastructure and pioneering the transformation toward a sustainable industry.